echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > JNNP: Application of plasma biomarkers in AT(N) classification of neurodegenerative dementia

    JNNP: Application of plasma biomarkers in AT(N) classification of neurodegenerative dementia

    • Last Update: 2021-06-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Cerebrospinal fluid amyloid Aβ1–42, total Tau (tTau) and phosphorylated Tau on threonine 181 (pTau181), are important biomarkers for Alzheimer's disease (AD) and are currently included in the national elderly Alzheimer’s It is used in the medical guidelines of the Institute of Murder Society for the diagnosis of AD in a research environment
    .


    Many centers in the world have adopted a ratio of 1-40 (ratio of 1-40) to diagnose AD early


    diagnosis

    Plasma tTau lacks disease specificity in AD, but it recognizes neuronal damage well in acute brain diseases
    .


    Simoa technology also allows the quantification of neurofilament (NfL) in plasma or serum, and shows a good correlation with the measurement results in cerebrospinal fluid


    In the current work, the effects of plasma levels of A, T and N markers (Aβ, pTau181 and NfL) on patients with different neurodegenerative dementias are quantified
    .


    The correlation between plasma biomarkers and biomarkers in cerebrospinal fluid was evaluated, and their respective diagnostic accuracy was evaluated to detect the plasma level of each type of marker


    The correlation between plasma biomarkers and biomarkers in cerebrospinal fluid was evaluated, and their respective diagnostic accuracy was evaluated to detect the plasma level of each type of marker


    Correlation between AT(N) plasma biomarkers and AT(N) cerebrospinal fluid biomarkers

    A total of 150 participants from the SPIN cohort were included, including MCI (n=46), AD (n=8), DLB (n=25), FTLD-related syndromes (n=25) and 46 CN participants
    .


    The FTLD-related clinical syndrome group includes behavioral variant frontotemporal dementia (n=10), primary progressive aphasia (n=8), cortical basilar artery syndrome (n=4), and progressive supranuclear palsy ( n=2) and frontotemporal dementia related to motor neuron disease (n=1)


    The diagnostic accuracy of AT(N) plasma biomarkers on the cerebrospinal fluid (CSF) section

    The area under the curve (AUC) of plasma Aβ, pTau181, and NfL were 0.
    75, 0.
    78, and 0.
    88, respectively, which were used to distinguish between positive and negative participants in the A, T, and N categories
    .


    In distinguishing A+T+ and AT- subjects, the combination of these three indicators is not superior to pTau181 alone (AUC=0.


    Plasma biomarkers help to detect the type of AT (N), and its application can be distinguished from the pathophysiological evidence of AD, and blood AT (N) markers are helpful for early diagnosis and follow-up of AD
    .

    Plasma biomarkers help to detect the type of AT (N), and its application can be distinguished from the pathophysiological evidence of AD, and blood AT (N) markers are helpful for early diagnosis and follow-up of AD
    .


    AlcoleaD ,DelabyC ,MuñozL AlcoleaD Alcolea DelabyC Delaby MuñozL Muñoz , et al Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias Journal of Neurology, Neurosurgery & PsychiatryPublished Online First:08 June 2021.
    Published Online First: doi:10.
    1136/jnnp-2021-326603 doi: leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.